Xin Hu

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Venues

Fudan University Shanghai Cancer Center

Shanghai Cancer Institute, Fudan University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fudan University Shanghai Cancer Center Apr 01 2012

China

Associate Professor, PI :: Key Laboratory of Breast Cancer in Shanghai

University of Texas MD Anderson Cancer Center Dec 06 2009 - Mar 07 2012

United States

Postdoc :: Genetics

Shanghai ChemPartner Co Ltd Mar 01 2008 - Oct 15 2009

China

Group Leader :: Biology

Education History

Shanghai Cancer Institute, Fudan University Sep 01 2003 - Jun 30 2008

China

PHD :: Shanghai Cancer Institute

Shanghai Medical College, Fudan University Sep 01 1998 - Jun 30 2003

China

BSC :: Basic Medical Sciences

Publications

Wenxiao Yang, Luo Hong, Linwei Guo, Yunjin Wang, Xiangchen Han, Boyue Han, Zheng Xing, Guoliang Zhang, Hongxia Zhou, Chao Chen, Hong Ling, Zhimin Shao, Xin Hu
Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer. Cell discovery 10 (1) (2024)
Boyue Han, Xiangchen Han, Hong Luo, Javaria Nasir, Chao Chen, Zhiming Shao, Hong Ling, Xin Hu
Multiomics and single-cell sequencings reveal the specific biological characteristics of low Ki-67 triple-negative breast cancer. Cancer innovation 3 (5) (2024)
Chao Chen, Cai-Jin Lin, Yu-Chen Pei, Ding Ma, Li Liao, Si-Yuan Li, Lei Fan, Gen-Hong Di, Song-Yang Wu, Xi-Yu Liu, Yun-Jin Wang, Qi Hong, Guo-Liang Zhang, Lin-Lin Xu, Bei-Bei Li, Wei Huang, Jin-Xiu Shi, Yi-Zhou Jiang, Xin Hu, Zhi-Ming Shao
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell discovery 9 (1) (2023)
Xun-Xi Lu, Wen-Xiao Yang, Yu-Chen Pei, Hong Luo, Xiaoguang Li, Yun-Jin Wang, Guo-Liang Zhang, Hong Ling, Zhiming Shao, Xin Hu
An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression. Cancer research (2023)
Chao Chen, Cai-Jin Lin, Yu-Chen Pei, Ding Ma, Li Liao, Si-Yuan Li, Lei Fan, Gen-Hong Di, Song-Yang Wu, Xi-Yu Liu, Yun-Jin Wang, Qi Hong, Guo-Liang Zhang, Lin-Lin Xu, Bei-Bei Li, Wei Huang, Jin-Xiu Shi, Yi-Zhou Jiang, Xin Hu, Zhi-Ming Shao
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell discovery 9 (1) (2023)
Haiyun Li, Linwei Guo, Chenchen Wang, Xin Hu, Ye Xu
Improving the value of molecular testing: current status and opportunities in colorectal cancer precision medicine. Cancer biology & medicine (2023)
Lin-Wei Guo, Xiao-Guang Li, Yun-Song Yang, Xun-Xi Lu, Xiang-Chen Han, Guan-Tian Lang, Li Chen, Zhi-Ming Shao, Xin Hu
Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated-PI3Kα in early and advanced HER2-positive breast cancer. Clinical and translational medicine 11 (11) (2022)
Peng Ji, Yue Gong, Ming-Liang Jin, Huai-Liang Wu, Lin-Wei Guo, Yu-Chen Pei, Wen-Jun Chai, Yi-Zhou Jiang, Yin Liu, Xiao-Yan Ma, Gen-Hong Di, Xin Hu, Zhi-Ming Shao
In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Science advances 8 (26) (2022)
Yue Gong, Jing Zhang, Peng Ji, Hong Ling, Xin Hu, Zhi-Ming Shao
Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer medicine 7 (8) (2018)

Xin Hu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xin Hu